Merck Serono signs five year framework agreement with Kadimastem
The new platform developed by Kadimastem permits usage of human functional tissues produced industrially from pluripotent stem cells as a way to search for potential new drugs. The
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.